Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von SERVIER
EUROPA-Studie (Perindopril) (60 Abbildungen)
Übersicht
Gesamtpräsentation zum Download (rechte Maustaste und "Ziel speichern unter..." klicken)


Zum ersten Bild Abb. 53: EUROPA-Studie - Interaktionsanalyse Abb. 54: EUROPA-Studie - Benefits Abb. 55: EUROPA-Studie - HOPE-Studie Abb. 56: EUROPA-Studie - HOPE-Studie Aktuelles Bild - Abb. 57: EUROPA-Studie - HOPE-Studie Abb. 58: EUROPA-Studie - Ergebnisse Abb. 59: EUROPA-Studie - Benefit Abb. 60: EUROPA-Studie - Ergebnisse
Abbildung 57: EUROPA-Studie - HOPE-Studie
At a mean follow-up of 4.5 years, HOPE reported a placebo mortality of 12%, cardiovascular mortality of 8 %, and Q-wave myocardial infarction of 3 %, compared with 7 %, 4 %, and 2 %, respectively, in EUROPA study at 4.2 years of follow-up. Thus, the major annual event rates in HOPE were 40 % to 80 % higher than those in EUROPA.
 
EUROPA-Studie - HOPE-Studie
Vorheriges Bild Nächstes Bild   


Abbildung 57: EUROPA-Studie - HOPE-Studie
At a mean follow-up of 4.5 years, HOPE reported a placebo mortality of 12%, cardiovascular mortality of 8 %, and Q-wave myocardial infarction of 3 %, compared with 7 %, 4 %, and 2 %, respectively, in EUROPA study at 4.2 years of follow-up. Thus, the major annual event rates in HOPE were 40 % to 80 % higher than those in EUROPA.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung